General news

Clinical Djokovic destroys Goffin to reach Wimbledon semi-finals

Published

on


Top seed Novak Djokovic recovered from an edgy start to deliver a devastating display which crushed the spirit of 21st-seeded Belgian David Goffin in straight sets on Wednesday.


The win sent the defending champion surging into the Wimbledon semi-finals.

Goffin will wonder just what happened after he looked the better player in the early stages and broke for a 4-3 lead in the first set.

Half an hour later he had lost 10 games in a row and the match was effectively over as Djokovic went on to triumph 6-4 6-0 6-2.

The 32-year-old Serb was at his clinical best as he soaked up the early punches without panic.

He then imposed himself in every aspect of the contest to such an extent that Goffin, 28, was left flailing on Centre Court.

Djokovic, who has lost only once at a Grand Slam in the last 12 months, is into his ninth Wimbledon semi-final —- only Jimmy Connors and Roger Federer have been in more.

In the last four, he will face Spanish world number 22 Roberto Bautista Agut.

Djokovic has reached the semi-finals having dropped one set and has been broken only five times in five matches and was delighted with how Wednesday’s match eventually unfolded.

“He started well and was dictating the play from the baseline,” he said. “Things could have gone a different way —- who knows what the match would have looked like if I had lost the first set?

“I think it was the turning point, it was a huge relief for me mentally. I started relaxing, going through the ball a bit more and I felt like I managed to dismantle his game and
find the right shots.”

It is not an uncommon pattern for the outsider to come out swinging and look dangerous, only to fall away, but the contrast was particularly extreme on Wednesday.

The Belgian was clearly the better player for much of the first set.

Though Djokovic saved break points in early games but he could not prevent Goffin cashing in on more in the seventh as, showing great court speed, he broke for 4-3.

The crowd settled down for what they thought might be a classic battle but it proved to be the high water mark for Goffin.

Djokovic started to find his return range, broke back immediately, held without trouble and broke again to bag the set.

Goffin, from dominating the rallies, was suddenly having to work desperately hard to stay in them, usually failing.

As Djokovic’s accuracy improved, particularly his service returns, his opponent’s slipped dramatically and he played a horror game to lose serve again to love and slide to 4-0 down.

He was then quickly 6-0 as he conceded the second set.

Goffin then received what all pros must hate —- the Centre Court sympathy clap —- when he finally held serve for 1-1 in the third set.

But he was barely going through the motions after that as the Serb cruised through to finish off the match in less than two hours.

“As soon as he was a break down he started to play a little bit. Everything was a little bit deeper, he served a little bit better and it was tough after that,” Goffin said.

“Even if you play well, it’s not enough because he continues to play deep, deep, close from the line, left, right. Amazing backhand down the line, as well. He was everywhere.”(Reuters/NAN)
OLAL

(Edited by Olawale Alabi)

https://nnn.ng/clinical-djokovic-destroys-goffin-to-reach-wimbledon-semi-finals/

Health

Clinical trials underway to evaluate plasma of COVID-19 recovered patients — WHO

Published

on


The World Health Organisation (WHO) says, clinical trials are underway to evaluate the effectiveness of using plasma from the blood of recovered COVID-19 patients, to reduce the severity of illness among people infected with the virus.
WHO Regional Director for Africa, Dr Matshidiso Moeti said this in her message to mark the 2020 World Blood Donor Day (WBDD).
WBDD is celebrated every June 14, to raise awareness on the need for safe blood and blood products, and to thank blood donors for their life-saving gifts of blood.
“This approach was used by Guinea in the Ebola epidemic in 2014, prior to the availability of Ebola vaccines and therapies.
“In Mauritius, 150 people who have recovered from COVID-19 have indicated they are willing to give plasma in line with the national decision to use serum plasma therapy for COVID-19 patients in intensive care.
“The biggest challenge with this approach in many African countries, is the insufficient resources of national blood services to safely collect, process and store COVID-19 convalescent plasma in a quality-assured manner.
“However, the current pandemic is also an opportunity to improve this situation. Kenya, for instance, has allocated a portion of funding from the World Bank specifically to improving blood services during the pandemic,’’ Moeti said.


In the COVID-19 pandemic, she said the supply of safe blood was at risk, saying: “regular blood donation drives are being postponed, and stay-at-home orders and fear of infection are preventing donors from accessing services.

“Disruptions to the global supply chain also put countries at risk of shortages of critical supplies and equipment needed for blood donation and transfusion.’’

According to her, universal access to safe blood is a key component of a resilient health system and contributes to achieving universal health coverage.
“In the African Region, countries are making progress in improving access to quality-assured blood and blood products.
“In 2019, eight countries collected 10 units or more per 1000 population as recommended by WHO and 19 countries reached the target of over 80 per cent voluntary non-remunerated blood donations in line with the regional strategy for blood safety.
“At WHO, we are also exploring partnerships with Facebook to set-up a regional Blood Donations feature, and 15 countries have expressed interest in piloting this tool.
“The feature connects blood donors with nearby opportunities to donate in collaboration with approved blood banks.’’
The regional director, however, urged governments, in collaboration with blood donor associations and non-government organisations, to increase investment in blood transfusion services in line with WHO guidance.
“I wish to thank all voluntary, unpaid blood donors for the life-saving gifts they offer to communities and all the phlebotomists.
“I also thank other health workers who contribute to blood donation and transfusion services – because of your commitment, safe blood saves lives,’’ she said.
According to her, On June 14, every year, the African Region joins the global community in celebrating World Blood Donor Day, because blood donors give the gift of life, and more lives will be saved if more people volunteer to donate blood on a regular basis.

“This year we are calling on people to “give blood and make the world a healthier place” because by regularly volunteering to donate blood, we can all contribute to solidarity and saving lives.
“Safe blood is a critical resource in severe infant anaemia, postpartum hemorrhage and trauma care. It is also vital in surgeries and the treatment of malaria, sickle cell disease, thalassemia, inherited blood disorders, and AIDS.’’

Edited By: Tayo Ikujuni/Ali Baba-Inuwa (NAN)

 

 

 

 

https://nnn.ng/clinical-trials-underway-to-evaluate-plasma-of-covid-19-recovered-patients-who/
Continue Reading

Foreign

Clinical tests begin for German-U.S. coronavirus vaccine 

Published

on


A German-U.S. coronavirus vaccine has been administered to human test subjects in the U.S., the companies involved reported on Tuesday.


After preliminary tests in Germany, Biontech of Mainz and U.S.-based Pfizer are advancing the clinical trial of BNT162, an mRNA vaccine, in the U.S.

As many as 360 healthy volunteers will be vaccinated in U.S. study — initially only with test subjects between ages 18 and 55 but later also with older participants.

The next round of tests in Germany will involve 200 healthy volunteers age 18 to 55, overseen by Paul Ehrlich Institute, Germany’s federal institute for vaccines.

The first results should be available in June.

If initial tests show a positive result, the tests will continue with more healthy participants as well as high-risk people.

Edited By: Emmanuel Yashim (NAN)

https://nnn.ng/clinical-tests-begin-for-german-u-s-coronavirus-vaccine/
Continue Reading

Foreign

Spotlight: Clinical trial shows remdesivir accelerates recovery from advanced COVID-19 patients

Published

on

By


Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a release from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) on Wednesday.


The conclusion came out of preliminary data analysis from a randomized, controlled trial involving 1,063 patients, which began on Feb. 21.

Preliminary results indicated that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo, according to the release.

Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo.

The results also suggested a survival benefit, with a mortality rate of 8 percent for the group receiving remdesivir versus 11.6 percent for the placebo group.

An independent data and safety monitoring board overseeing the trial met on April 27 to review the data and shared their interim analysis with the study team.

Based upon their review of the data, the board members noted that remdesivir was better than placebo from the perspective of primary endpoint, or patients’ time to recovery. It is a metric often used in influenza trials.

The first participant in the trial was an American who was repatriated after being quarantined on the Diamond Princess cruise ship that docked in Yokohama, Japan.

The patient volunteered to participate in the study at the first study site, the University of Nebraska Medical Center, in February 2020, according to the NIAID.

A total of 68 sites ultimately joined the study, 47 in the United States and 21 in countries in Europe and Asia.

The trial, sponsored by the NIAID, part of the National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.

Remdesivir, developed by American biopharmaceutical company Gilead Sciences, is an investigational broad-spectrum antiviral treatment administered via daily infusion for 10 days. It is not yet licensed or approved anywhere globally while multiple Phase 3 studies are ongoing to determine the safety and efficacy of the drug for the treatment of COVID-19.

Gilead also announced preliminary results of phase 3 trial of remdesivir in patients with severe COVID-19, showing more than half of patients in both 5-day and 10-day treatment groups were discharged from the hospital after two weeks.

The trial evaluated 5-day and 10-day dosing durations of remdesivir in hospitalized patients with severe COVID-19. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course, according to Gilead Sciences.

“At Day 14, 64.5 percent of patients in the 5-day treatment group and 53.8 percent of patients in the 10-day treatment group achieved clinical recovery,” the company said in a statement.

No new safety signals were identified with remdesivir across either treatment group.

“Multiple concurrent studies are helping inform whether remdesivir is a safe and effective treatment for COVID-19 and how to best utilize the drug,” said Merdad Parsey, chief medical officer of Gilead Sciences.

“While additional data are still needed, these results help to bring a clearer understanding of how treatment with remdesivir may be optimized, if proven safe and effective,” said Aruna Subramanian, clinical professor of medicine at Stanford University School of Medicine, and one of the lead investigators of the study.

Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.

These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19, according to Gilead.

Anthony Fauci, director of the NIAID, said Wednesday he was told data from the trial showed a “clear cut positive effect in diminishing time to recover.”

Remdesivir has shown some promise in treating SARS and MERS, which are also caused by coronaviruses. As there is currently no cure for treating COVID-19, health authorities around the world have pinned hopes on drugs such as remdesivir to reduce the duration of COVID-19 in patients.

(XINHUA)

https://nnn.ng/spotlight-clinical-trial-shows-remdesivir-accelerates-recovery-from-advanced-covid-19-patients/
Continue Reading

Foreign

Clinical trial shows remdesivir accelerates recovery from advanced COVID-19 patients

Published

on

By


Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a release from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) on Wednesday.


The result came out of preliminary data analysis from a randomized, controlled trial involving 1,063 patients, which began on Feb. 21.

Preliminary results indicated that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo, according to the release.

Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo.

Results also suggested a survival benefit, with a mortality rate of 8 percent for the group receiving remdesivir versus 11.6 percent for the placebo group.

An independent data and safety monitoring board overseeing the trial met on April 27 to review the data and shared their interim analysis with the study team.

Based upon their review of the data, the board members noted that remdesivir was better than placebo from the perspective of primary endpoint, or patients’ time to recovery. It is a metric often used in influenza trials.

The first participant in the trial was an American who was repatriated after being quarantined on the Diamond Princess cruise ship that docked in Yokohama, Japan.

The patient volunteered to participate in the study at the first study site, the University of Nebraska Medical Center, in February 2020, according to the NIAID.

A total of 68 sites ultimately joined the study, 47 in the United States and 21 in countries in Europe and Asia.

The trial, sponsored by the NIAID, part of the National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.

Gilead Sciences, an American biopharmaceutical company, also announced preliminary results of phase 3 trial of remdesivir in patients with severe COVID-19, showing more than half of patients in both 5-day and 10-day treatment groups were discharged from the hospital after two weeks.

The trial evaluated 5-day and 10-day dosing durations of remdesivir in hospitalized patients with severe COVID-19. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course, according to Gilead Sciences.

“At Day 14, 64.5 percent of patients in the 5-day treatment group and 53.8 percent of patients in the 10-day treatment group achieved clinical recovery,” the company said in a statement.

No new safety signals were identified with remdesivir across either treatment group.

Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.

These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19, according to Gilead.

(XINHUA)

https://nnn.ng/clinical-trial-shows-remdesivir-accelerates-recovery-from-advanced-covid-19-patients/
Continue Reading

Damilare, Christiana emerge winners in Big Dreams Nigeria talent show NCDC announces 176 new COVID-19 infection in Nigeria UNGA Debate: Buhari urges global action against small arms S/Arabia to allow Umrah pilgrimage to resume from October – Report UNGA Debate: Buhari advocates uninhibited supply of safe coronavirus vaccines to all Nigeria High Commission in Canada reopens after six-month closure President Buhari’s UNGA75 National Statement Olowu condoles with COAS, says Col. Bako’s death a national tragedy 9 energy firms get $2.6m USAID grant to power rural clinics in Africa FCTA reiterates commitment to job creation through agriculture value chain Sanwo-Olu charges cabinet, officials to brace up for optimum performance I never accused NAN staff of fraud, says Lagos NUJ Chairman Navy deploys 6 warships for special military operation in 4 states Obiano inaugurates 18-member task force on human trafficking, irregular migrationar migration Buhari congratulates Plateau Dep. Gov. Tyoden at 70 Barbados tourism expert advises African operators on innovation Ramaphosa urges UN to take decisive action against racism Ex-governor Yari administration diverted N10.8bn for university project – Commissioner  Buhari consoles with Borno on loss of two Emirs Suspect wanted by FBI for $6m scam surrenders to EFCC — Official Lagos govt to train medical records personnel for effective service delivery AbdulRazaq updates Buhari on Kwara flood disaster, seeks FG support   Flood: NASG distributes relief materials to victims in 45 communities UN commends FG on improvement of humanitarian access in North-East Gov. Ganduje inaugurates NYSC governing board 8 states yet to implement new minimum wage – TUC COVID-19: We’ve flattened the curve, says Gov. Ganduje Silverbird Group to establish cinema outlets in Ebonyi FG alleges that multinationals companies drill for water without approval Electricity/Fuel pump hike: NLC insists on nationwide protest LASG receives 107,546 CA-COVID food palliative packs At UNGA, AU chairman solicits ‘comprehensive stimulus package’ for Africa Sanusi calls for diversification of economy to address poverty, inequality Food Council to ensure reduction in fertiliser price – Gov. Bagudu Kwara Assembly urges Gov AbdulRasaq to assist rainstorm victims I’m loyal to APC, not factions, says chieftain in Ibadan Oyo govt re-awards 9.7km Saki township road for N4.7bn Suarez language exam for Italian citizenship rigged, prosecutors insist Runsewe urges youths to uphold cultural values Late Emir of Zazzau was a father to all – NDA Spurs’ League Cup match called off due to COVID-19 cases at Orient Mixed reactions trail CBN‘s MPR cut 40 coys bid for NEPZA constituency projects Bale may extend Spurs’ stay beyond loan spell, agent says Minister urges fertilizer dealers to work in line with Fertilizer Act IBEDC apologises to customers over poor electricity supply NAICOM urges state govts to domesticate compulsory life insurance, others for citizens Minister advocates return of state sports festivals to enhance athletes’ competitiveness PMAN congratulates King Sunny Ade at 74 FRC partners agencies on monitoring, evaluation, project verification